| Code | CSB-RA023984MB17HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to YH-004, targeting TNFRSF9 (Tumor Necrosis Factor Receptor Superfamily Member 9), also known as 4-1BB or CD137. TNFRSF9 is an inducible costimulatory receptor expressed primarily on activated T cells and natural killer cells, playing a critical role in regulating immune cell activation, proliferation, and survival. Upon binding with its ligand 4-1BBL, TNFRSF9 enhances T cell-mediated immune responses and promotes anti-tumor immunity. This pathway has significant implications in cancer immunotherapy, autoimmune diseases, and viral infections, making TNFRSF9 an important therapeutic target for modulating immune responses.
YH-004 is a reference antibody that has been investigated for its immunomodulatory properties in preclinical and clinical research settings. This biosimilar antibody serves as a valuable research tool for investigating TNFRSF9 signaling mechanisms, studying immune checkpoint modulation, and exploring therapeutic strategies in oncology and immunology research. It enables researchers to examine T cell costimulation pathways and evaluate potential immunotherapeutic approaches in various experimental models.
There are currently no reviews for this product.